Our group has been interested in the clinical development of hydralazine and valproate a DNA methylation and histone deacetylases (HDAC) inhibitors respectively as epigenetic therapy for cancer including cervical carcinoma [19-24]. This evidence concerns the gene HDAC9 and cervical carcinoma.